Showing results (61-70 of 105) with videos related to
Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
Pan-Tumor Pathologic Scoring of Response to PD-(L)1 BlockadeJulie E Stein, Evan J Lipson, Tricia R Cottrell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2003
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanomaSteven A Rosenberg, James C Yang, Douglas J Schwartzentruber, et al.Cell|August 30, 2011
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1Eric V Dang, Joseph Barbi, Huang-Yu Yang, et al.Cell Reports. Medicine|February 10, 2024
Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinomaThomas Pulliam, Saumya Jani, Lichen Jing, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2023
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung CancerSamuel Rosner, Joshua E Reuss, Marianna Zahurak, et al.Nature Communications|February 3, 2025
A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer typesZhen Zeng, Tianbei Zhang, Jiajia Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanomaKimberly R Lindsey, Linda Gritz, Richard Sherry, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 10, 2002
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanomaMark E Dudley, John R Wunderlich, James C Yang, et al.Journal for Immunotherapy of Cancer|June 4, 2021
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trialRobert L Ferris, William C Spanos, Rom Leidner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2019
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 TrialR Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.Pageof 11